02093nas a2200553   4500000000100000000000100001008004100002260001500043653001700058653001900075100001600094700002400110700002100134700002600155700001800181700002000199700002500219700002400244700001900268700002600287700002000313700002300333700002000356700001900376700002200395700002200417700002600439700002100465700002100486700002000507700002400527700002100551700001900572700002400591700002600615700001600641700001600657700002000673700003100693700002100724700002100745700001800766245009700784856005500881300000800936490000600944520057500950022001401525       2022                            d  c2022-12-0610aCell biology10aDrug Discovery1 aLorna Ewart1 aAthanasia Apostolou1 aSkyler A. Briggs1 aChristopher V. Carman1 aJake T. Chaff1 aAnthony R. Heng1 aSushma Jadalannagari1 aJeshina Janardhanan1 aKyung-Jin Jang1 aSannidhi R. Joshipura1 aMahika M. Kadam1 aMarianne Kanellias1 aVille J. Kujala1 aGauri Kulkarni1 aChristopher Y. Le1 aCarolina Lucchesi1 aDimitris V. Manatakis1 aKairav K. Maniar1 aMeaghan E. Quinn1 aJoseph S. Ravan1 aAnn Catherine Rizos1 aJohn F. K. Sauld1 aJosiah D. Sliz1 aWilliam Tien-Street1 aDennis Ramos Trinidad1 aJames Velez1 aMax Wendell1 aOnyi Irrechukwu1 aPrathap Kumar Mahalingaiah1 aDonald E. Ingber1 aJack W. Scannell1 aDaniel Levner00aPerformance assessment and economic analysis of a human Liver-Chip for predictive toxicology  uhttps://www.nature.com/articles/s43856-022-00209-1  a1540 v23 aConventional preclinical models often miss drug toxicities, meaning the harm these drugs pose to humans is only realized in clinical trials or when they make it to market. This has caused the pharmaceutical industry to waste considerable time and resources developing drugs destined to fail. Organ-on-a-Chip technology has the potential improve success in drug development pipelines, as it can recapitulate organ-level pathophysiology and clinical responses; however, systematic and quantitative evaluations of Organ-Chips’ predictive value have not yet been reported.  a2730-664X